Equities Analysts Offer Predictions for Insulet Q4 Earnings

Insulet Co. (NASDAQ:PODD) – Analysts at William Blair increased their Q4 2024 earnings estimates for shares of Insulet in a research note issued to investors on Monday, November 11th. William Blair analyst M. Andrew now forecasts that the medical instruments supplier will post earnings of $1.18 per share for the quarter, up from their prior estimate of $0.99. The consensus estimate for Insulet’s current full-year earnings is $3.17 per share. William Blair also issued estimates for Insulet’s Q1 2025 earnings at $0.83 EPS, Q2 2025 earnings at $0.84 EPS and FY2025 earnings at $3.91 EPS.

Several other analysts have also recently issued reports on PODD. Barclays increased their target price on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday. Morgan Stanley lifted their target price on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday. Canaccord Genuity Group increased their price target on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Piper Sandler boosted their target price on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Finally, Raymond James increased their price target on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Price Performance

Shares of PODD stock opened at $269.06 on Wednesday. Insulet has a twelve month low of $160.19 and a twelve month high of $279.40. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a fifty day simple moving average of $235.96 and a two-hundred day simple moving average of $206.47. The stock has a market capitalization of $18.87 billion, a price-to-earnings ratio of 46.07, a P/E/G ratio of 4.26 and a beta of 1.22.

Institutional Investors Weigh In On Insulet

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new position in Insulet in the 2nd quarter valued at about $99,978,000. Baillie Gifford & Co. lifted its holdings in shares of Insulet by 30.8% during the second quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock worth $380,607,000 after purchasing an additional 443,783 shares during the period. Mizuho Securities USA LLC grew its position in Insulet by 5,928.1% in the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock valued at $75,835,000 after buying an additional 320,416 shares during the last quarter. Canada Pension Plan Investment Board increased its stake in Insulet by 206.9% in the 1st quarter. Canada Pension Plan Investment Board now owns 429,591 shares of the medical instruments supplier’s stock valued at $73,632,000 after buying an additional 289,591 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after buying an additional 193,839 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.